Adenosan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adenosan

Adenosan is a name for a medication whose core component is Ketoconazole, a synthetic small-molecule compound primarily defined by its effectiveness against fungal pathogens. It is fundamentally an agent designed to stop the growth and spread of infections caused by fungi and yeast throughout the body or on the skin's surface.

Property Description
Active Ingredient Ketoconazole (INN)
Form Oral tablet, Cream, Shampoo, Gel
Pharmacological Class Azole antifungal (Imidazole derivative)
Common Use Control of fungal and yeast infections (systemic and topical)
Origin Synthetic

Adenosan: Chemical Identity and Pharmacological Class

The active ingredient in Adenosan is Ketoconazole, a synthetic agent classified as an Azole antifungal and an Imidazole derivative. This chemical classification places it in a specialized group of medicines engineered to interfere with the metabolic processes unique to fungal organisms, distinguishing it from antibacterial or antiviral compounds.

The Ketoconazole molecule's structure defines its mechanism and range of action. Its identity as an Imidazole derivative means it targets specific fungal pathways involved in cell structure maintenance, providing a consistent and targeted therapeutic action against a broad spectrum of yeast and mold infections. The substance is clinically recognized for its versatility in addressing fungal issues affecting both internal systems and external surfaces, such as the skin.

Forms, Delivery Types, and General Purpose

Adenosan is made available in different formulations to treat infections requiring either internal or external intervention, including the oral tablet for systemic use and various topical formulations such as cream and shampoo. This versatility allows the drug to be delivered appropriately, either via the oral route to reach deep-seated internal infections, or via the topical route for localized skin and scalp issues.

The general therapeutic purpose of all forms is to exert a fungistatic agent effect, which means it limits the growth and multiplication of the fungal population. Furthermore, Ketoconazole acts as an inhibitor of ergosterol synthesis, which is its primary mechanism of action against fungi.


Understanding the Ketoconazole Mechanism (High-Level Concept)

Ketoconazole works by disrupting the essential protective layer of the fungal cell, a membrane critical for survival and growth. It achieves this by selectively blocking the fungus’s ability to manufacture ergosterol, the primary building block of this cell membrane. This targeted inhibition causes the fungal cell walls to become leaky and structurally unsound, which effectively halts the proliferation of the infectious agent.

Regulatory References

  1. Ketoconazole Topical (MedlinePlus)

What side effects are possible with Adenosan?

Possible Side Effects and Safety Information

Adenosan (Adenosine) is associated with a safety profile primarily involving cardiovascular and respiratory events due to its pharmacological action. Adverse reactions are typically transient due to the drug’s extremely short half-life in the body, but can be significant.

Serious and Clinically Significant Adverse Reactions

Regulatory warnings emphasize the potential for serious, life-threatening events, including cardiac arrest, sustained ventricular tachycardia, and myocardial infarction (heart attack). Other serious risks include the development of first-, second-, or third-degree atrioventricular (AV) block and severe sinus bradycardia (abnormally slow heart rate).

Common Adverse Reactions

Adverse reactions that occur frequently (Very Common or Common) include:

  • Cardiovascular: Flushing, chest discomfort or pressure, headache, hypotension (low blood pressure).
  • Respiratory: Shortness of breath (dyspnea).
  • General: Throat, neck, or jaw discomfort, lightheadedness, dizziness, and gastrointestinal discomfort.

Safety Restrictions and Contraindications

The use of Adenosan is formally contraindicated in patients with:

  1. Second- or third-degree AV block or sick sinus syndrome (Sinus Node Dysfunction), unless a functioning artificial pacemaker is present.
  2. Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
  3. Known hypersensitivity to Adenosan.

Population and Monitoring Notes

Caution is advised for patients with certain pre-existing conditions, such as first-degree AV block, specific cerebrovascular conditions, or uncorrected hypovolemia. Due to the drug’s cardiovascular effects, continuous electrocardiogram (ECG) and blood pressure monitoring are required during administration to manage transient rhythm disturbances or hemodynamic changes.

Overdose and Emergency Response

An overdose of oral Adenosan (Ketoconazole) is officially documented to present with signs of acute systemic toxicity, primarily affecting the liver. Documented manifestations include jaundice (yellowing of the skin or eyes), dark urine, pale stools, nausea, vomiting, anorexia, and fatigue. Severe outcomes noted in regulatory information include potentially fatal hepatotoxicity, adrenal insufficiency, QT prolongation, and life-threatening ventricular dysrhythmias.

These severe outcomes necessitate immediate emergency actions. Urgent medical attention is required for any signs of liver damage or cardiac distress, such as a fast, pounding, or irregular heartbeat. Emergency services (911) must be contacted immediately if the individual experiences collapse, seizures, trouble breathing, or loss of consciousness.

The official management approach is symptomatic and supportive treatment, as no specific antidote is known. Depending on the time since ingestion, procedures like gastric lavage or activated charcoal may be considered. Close monitoring of fluid/electrolyte balance and blood pressure is required. In cases where adrenal insufficiency is suspected, regulatory guidance requires the administration of hydrocortisone with saline and glucose infusion. Overdose risks are specifically tied to the oral tablet; topical formulations have no documented experience with systemic overdose.

Therapeutic Uses of Adenosan

What Adenosan Treats: Main Uses and Benefits

This medication is relevant across therapeutic domains involving fungal and yeast pathogens. It is used in situations involving certain distressing symptoms where specific antifungal support is needed. This medication is applied in managing both superficial and systemic fungal infections and is commonly used to address various symptomatic conditions.

The medication is commonly used to help manage fungal and yeast infections such as severe, disseminated internal fungal diseases (like Histoplasmosis and Coccidioidomycosis), superficial fungal infections (including athlete's foot, ringworm, and jock itch), and chronic, yeast-driven skin issues like seborrheic dermatitis and severe dandruff. Adenosan helps address symptom clusters of intense itching, burning, flaking, scaling, and redness.

“It is commonly used to help manage symptoms associated with both acute skin episodes and significant internal fungal burdens.”

This medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. It is applied in clinical settings where supportive symptom management is appropriate and assists in managing the infection across these varying clinical contexts.


Key Therapeutic Focus: Relief for Itching, Burning, and Scaling

This medication is commonly used to help manage symptoms related to inflammatory or irritative states and may assist with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview of Ketoconazole Topical

Eligibility and Restrictions for Use

Eligibility and Contraindications

Adenosan (Ketoconazole) oral tablets are a restricted-use medication, and official regulatory labeling sets strict rules on patient eligibility.

Absolute Contraindications

The medicine is contraindicated in patients with known hypersensitivity to ketoconazole or any component of the formulation. It must not be used in individuals with pre-existing acute or chronic liver disease or those with elevated liver enzymes exceeding official limits. Use is also prohibited in patients with congenital or acquired QTc prolongation or a history of ventricular arrhythmias. It is contraindicated for specific conditions like fungal meningitis and for patients concurrently taking certain medications that interact significantly with it.

Restricted and Age-Related Use

Use is generally restricted to adults being treated for severe systemic fungal infections who have failed or cannot tolerate alternative effective therapies. It is not recommended for common superficial infections like skin or nail fungus. Safety and efficacy are not established in children under 2 years of age. Furthermore, the medicine is contraindicated or not recommended for women who are pregnant or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Adenosan is defined primarily by its documented role as a potent inhibitor of Cytochrome P450 3A4 (CYP3A4) and an inhibitor of P-glycoprotein (P-gp). This metabolic and transporter inhibition results in reduced clearance and elevated plasma concentrations of numerous co-administered medicinal products.

Contraindicated Combinations

Co-administration is contraindicated with certain medicines due to the high risk of severe adverse reactions from increased exposure. These include several cardiovascular agents associated with QT prolongation (e.g., Pimozide, Dofetilide), certain HMG-CoA reductase inhibitors (e.g., Lovastatin, Simvastatin) due to the risk of muscle toxicity, and specific ergot alkaloids (e.g., Ergotamine) due to the risk of vasospasm.

Absorption and Timing Rules

The absorption of Ketoconazole is significantly impaired by medicines that reduce gastric acidity (e.g., antacids, proton pump inhibitors). To prevent reduced efficacy, acid-neutralizing antacids must be administered at least 1 hour before or 2 hours after Adenosan. The label also advises avoiding alcohol consumption during treatment.

Population and Other Notes

Interactions with specific antibiotics or anti-gout medicines (e.g., Colchicine, Clarithromycin) carry an increased risk of severe toxicity in patients with severe renal impairment. Co-administration with potent CYP3A4 enzyme inducers (e.g., Rifampin) is not recommended as it may significantly lower Adenosan concentrations.

Mechanism of Action

Targeting Fungal Cell Membrane Synthesis

The drug's primary action is the non-competitive inhibition of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51). By blocking this critical step in the ergosterol biosynthesis pathway, the drug starves the fungal organism of the essential lipid required to construct its cell membrane, initiating a cascade that results in suppressed fungal cell growth and replication.

Inducing Intracellular Toxin Accumulation

Simultaneously, the blockade of the CYP51 enzyme causes a toxic build-up of structurally unsound precursor molecules, the 14alpha-methylated sterols, within the fungal cell. This accumulation, combined with the lack of ergosterol, structurally and functionally compromises the cell, contributing to a profound reduction in fungal cell viability and division.

Secondary Modulation of Host Hormonal Pathways

In addition to its fungal mechanism, the drug can inhibit certain human Cytochrome P450 enzymes involved in steroidogenesis (hormone synthesis). This secondary mechanism leads to a systemic consequence: the modulation of host steroid hormone production, resulting in decreased cortisol and testosterone levels.

Mechanism Constraints and Evasion

The mechanism's functional capacity is limited by biological constraints, such as poor blood-brain barrier penetration, which results in low drug concentration at targets within the Central Nervous System.

Dosage and Administration Information

Administration Guidelines for Adenosan (Ketoconazole)

Ketoconazole, the active agent in Adenosan, is administered via two primary routes: oral for systemic conditions and topical (cream, gel, foam, or shampoo) for localized skin and scalp issues. The usage pattern, dose, and frequency are defined by the intended route and specific use.

Oral Use Regimens

For systemic fungal infections, the usual starting dose for adults is 200 milligrams (mg) once daily, which may be increased to a maximum of 400 mg once daily. For children 2 years of age and older, the dose is determined by body weight, typically ranging from 3.3 to 6.6 mg/kg per day.

Oral administration is taken with a meal to enhance absorption. Furthermore, to maintain the required gastric acidity for drug dissolution, oral administration is separated from antacids or acid-reducing medications, which are taken at least 1 hour before or 2 hours after the dose. Systemic treatment duration is often long-term, lasting 6 months or longer, and continues for the full prescribed time. If a dose is missed, it is taken as soon as possible, but not doubled to catch up to the regular schedule.

Topical Administration

Topical forms are for cutaneous use only and must not be used on the eyes or taken orally. The 2% cream is generally applied once or twice daily to the affected and surrounding skin area, with treatment courses ranging from 2 to 6 weeks depending on the condition being addressed. The 2% shampoo requires application to the affected area, lathering, and is left in place for 5 minutes before rinsing for certain skin infections.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adenosan (Ketoconazole)

Evidence for Use in Seborrheic Dermatitis (Topical Application)

Research for topical use in seborrheic dermatitis is based on randomized controlled trials (RCTs) that examined patient populations over time-limited observation periods. Studies focused on outcomes related to inflammatory states and tracked changes in Symptom Scores for scaling and itching. This evidence has been categorized as High in some reviews, but long-term effects are not fully established beyond six months, and data for infants and very young children are limited.

Evidence for Use in Superficial Fungal Infections (Topical Dermatophytosis)

Research for conditions like athlete’s foot involved RCTs and comparative studies. Researchers monitored key outcomes, including the evaluation of a Mycological Cure and documenting changes in Symptom Scores related to physical discomfort. Trials directly comparing this agent with newer antifungal agents are limited. The current research level has been categorized as Moderate.

Evidence for Restricted Use in Systemic Fungal Diseases

The research structure for the oral tablet, used for severe, disseminated systemic fungal diseases, relies primarily on pre-market clinical studies and observational reviews, not current RCTs. Studies monitored outcomes such as overall Survival and measures of clinical status. Because this evidence is mainly historical and often involves patients who were studied when other established treatments were not used, certainty remains low in the current regulatory context.

Evidence Landscape for Pattern Hair Loss (Topical Shampoo)

Studies for Androgenetic Alopecia (AGA) included smaller-scale human studies exploring changes in Hair Shaft Diameter. Findings showed patterns related to conflicting results regarding measured Hair Density, and the consistency of results remains an area of scientific uncertainty. The evidence level is categorized as Low to Moderate.

Research Gaps and Areas of Uncertainty

Across all indications, long-term effects are not fully established as follow-up durations were often limited. Furthermore, trials directly comparing Ketoconazole and newer antifungal agents are limited due to regulatory restrictions on the oral route. The results apply only to the populations studied, meaning that subgroup findings are uncertain in many areas.

Key Studies & References

  1. NIH MedlinePlus: Ketoconazole Topical Antifungal Overview (Monograph on Use and Mechanism)
  2. WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index (Ketoconazole Classification)
  3. Clinical Guidelines on Diagnosis and Management of Superficial Fungal Infections (Dermatophytosis/Tinea)

Frequently Asked Questions (FAQ)

Common questions about Adenosan (FAQ)

Q: How does Adenosan compare generally to other drugs for the same condition?

A: Official regulatory documents indicate that Adenosan (ketoconazole oral tablet) is associated with a risk of serious side effects. Because of these safety concerns, its use is strictly limited and is restricted to conditions where alternative therapies are not available or have not been tolerated.

Q: Why do some patients stop taking Adenosan?

A: Discontinuation has occurred due to the development of serious liver problems, such as persistent or worsening liver enzyme elevations. Cessation may also be necessary due to other severe adverse reactions as listed in the official safety information.

Q: How long does the effect of one dose of Adenosan usually last?

A: The elimination of the medicine from the body occurs in two phases. The initial half-life (the time it takes for half the drug to be eliminated) is approximately 2 hours, followed by a longer terminal phase with a half-life of about 8 hours.

Q: Do I need to change my diet while using Adenosan?

A: Official guidelines state the oral tablet is taken with a meal for proper absorption into the body. Regulatory information also indicates that grapefruit and grapefruit juice should be avoided, as these can potentially raise the drug's levels in the blood.

Q: Are there any long-term side effects associated with Adenosan use?

A: Liver injury, known as hepatotoxicity, is a primary long-term risk associated with this medicine. Regulatory data indicates this adverse reaction has typically presented between one and six months after treatment initiation.

Q: What beverages, like alcohol or caffeine, should be avoided while using Adenosan?

A: Regulatory information describes the need to avoid or limit alcohol use while using this medicine. This is because alcohol may increase the risk of liver damage and could potentially trigger an unpleasant disulfiram-like reaction.

Q: What should I tell my doctor before starting Adenosan?

A: Official guidance indicates that information about all current medications, including prescriptions and over-the-counter products, should be reviewed with a healthcare professional. Any history of liver problems or heart rhythm issues should also be disclosed due to interaction and safety concerns.

Q: Do changes in weight affect how Adenosan works?

A: Regulatory documents indicate that the oral dose for children is calculated based on their body weight to ensure safety and effectiveness. While adult dosing is typically fixed, some drug-related hormonal side effects may involve changes in weight.

Q: Is Adenosan effective for all types of the condition it treats?

A: The oral tablet form of Adenosan is not approved for all types of fungal infections. It is specifically restricted for use only in severe systemic fungal infections and is not indicated for common skin or nail fungal issues.

Q: What common foods are known to interact with Adenosan?

A: Official guidelines state the oral tablet is taken with food to improve absorption into the bloodstream. Regulatory sources also indicate that grapefruit and grapefruit juice should be avoided, as they may impact the medicine's concentration in the body.

Q: Is Adenosan generally well-tolerated?

A: The official FDA label includes a Boxed Warning due to the serious risks of liver failure and heart rhythm problems. Its use is highly restricted, suggesting that its benefits are weighed against these significant potential risks.

Q: Can Adenosan be used for conditions other than its primary approved use?

A: The oral tablet is approved only for treating certain severe systemic fungal infections that are designated in the official prescribing information. It is not indicated for most common fungal infections, and its use is restricted to approved indications.

Q: Is there a generic version of Adenosan available?

A: Yes, the active ingredient in Adenosan, which is ketoconazole, is widely available. Official drug registers show that generic forms exist for both the oral tablet and the topical formulations.

Q: What is the time frame for Adenosan to start working?

A: For topical forms (creams, shampoos), patients may see initial clinical improvement relatively soon after beginning treatment. The time frame for the onset of action of the systemic (oral) form is not specifically detailed in the patient materials.

Q: Can Adenosan affect my ability to drive or operate machinery?

A: Official safety documents list side effects such as dizziness and somnolence (a state of drowsiness or strong desire for sleep). Official safety information indicates caution is generally warranted when performing tasks that require mental alertness.

Q: Is it normal to feel tired when you first start Adenosan?

A: Tiredness or unusual weakness is a potential side effect listed in official prescribing information. This can also be a symptom of a more serious adverse reaction, such as a liver problem or adrenal insufficiency.

Q: Does Adenosan interact negatively with common over-the-counter pain relievers?

A: Regulatory data indicates caution is warranted when co-administering this medicine with common pain relievers like ibuprofen or acetaminophen (paracetamol). Co-administration may increase the risk of potential liver damage.

Q: Is it safe to take Adenosan with supplements like vitamins or herbal remedies?

A: Regulatory guidance indicates that information about all products, including vitamins and herbal remedies, should be shared with a healthcare professional. Many supplements can interact with Ketoconazole, potentially affecting drug safety.

Q: What happens if I suddenly stop taking Adenosan?

A: If the medicine is discontinued due to the onset of liver problems, the liver injury is generally considered reversible. However, regulatory literature indicates that full recovery can take an extended period, often between one and three months.

Q: Does Adenosan have a 'black box warning' from the FDA?

A: Yes, the FDA prescribing information for the oral formulation of ketoconazole includes a Boxed Warning. This prominent safety warning highlights the serious potential for liver failure and life-threatening heart rhythm disturbances.

Q: Has Adenosan been withdrawn from use in any countries?

A: Oral formulations of ketoconazole for the treatment of fungal infections were suspended in 2013 in the European Union and certain other countries. This action was taken specifically due to concerns over the risk of liver injury.

Q: Is Adenosan a controlled substance?

A: According to regulatory classification, oral ketoconazole is listed as a prescription-only medication. However, it is not currently designated as a scheduled controlled substance.

Q: Can I take Adenosan if I have high blood pressure?

A: While high blood pressure is not an absolute contraindication, the drug can cause hypotension (low blood pressure) as a side effect. Due to its association with other cardiovascular issues, caution is advised for patients with pre-existing heart or circulation concerns.

Q: Does Adenosan affect blood sugar levels?

A: Official documents list hypoglycemia, or low blood sugar, as a rare adverse effect of the medicine. The drug is also known to interact with certain anti-diabetic drugs, which can lead to increased concentrations of those medicines.

Q: Are the side effects of Adenosan worse at the beginning of treatment?

A: Regulatory literature suggests that some side effects, such as transient and mild liver enzyme elevations, may appear early in the course of treatment. These initial effects have sometimes resolved on their own even when the patient continued taking the medicine.

Q: Can Adenosan interact with birth control pills?

A: Yes, official interaction data indicates that oral ketoconazole may increase the concentration of certain hormonal contraceptives in the bloodstream. This increase in concentration can sometimes lead to increased side effects such as nausea or unexpected vaginal bleeding.

Q: Do official prescribing documents list any mental health side effects for Adenosan?

A: Yes, official prescribing documents do report some psychiatric side effects. These include issues like insomnia and nervousness, and on rare occasions, more severe symptoms such as confusion and suicidal tendencies have been reported.

How should Adenosan be stored and disposed of?

The storage and disposal of Adenosan (Ketoconazole) must follow official regulatory requirements to ensure product stability and environmental safety.

Storage Conditions

Oral tablets should be stored at Controlled Room Temperature, typically between 15° to 30°C. They must be protected from moisture and kept in a tight, light-resistant container. Topical forms should generally be stored below 25°C and must be kept from freezing.

Flammable topical products, such as foams, must be kept away from fire, flame, and excessive heat above 49°C. All forms must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired medicine must be disposed of in accordance with local requirements. Medicines must not be thrown away via wastewater or household trash due to potential harm to the environment. Consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adenosan found in:

A-Z Index: